The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 31, No. 5, pp. 625-632.
© 1997 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lobo, B.
Right arrow Articles by Greene, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lobo, B.
Right arrow Articles by Greene, W.

Research Articles

Zolpidem: distinct from triazolam?

BL Lobo and WL Greene

OBJECTIVE: To review the literature that compares zolpidem with triazolam, with an emphasis on efficacy and safety in humans. DATA SOURCES: Information was retrieved from a MEDLINE search (1983-1996) of the English-language literature using the terms triazolam and zolpidem. STUDY SELECTION: Reports of clinical trials comparing the safety and efficacy of zolpidem and triazolam were included in this review. DATA EXTRACTION: Data were evaluated according to study design, efficacy, and adverse effects. Pertinent information was selected and the data synthesized into a review format. DATA SYNTHESIS: Zolpidem and triazolam have similar pharmacokinetic and pharmacodynamic effects in humans. Clinical trials have shown that usually recommended, equipotent dosages of zolpidem and triazolam do not differ with respect to pharmacokinetics, efficacy, tolerability, residual effects, memory impairment, rebound insomnia, abuse potential, or other adverse effects. CONCLUSIONS: Zolpidem offers no distinct therapeutic advantage over triazolam for the treatment of insomnia.


This article has been cited by other articles:


Home page
 J Geriatr Psychiatry NeurolHome page
J. O. Brooks and J. C. Hoblyn
Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults
J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. R Rappa, M. Larose-Pierre, D. R Payne, N. E Eraikhuemen, D. M Lanes, and M. L Kearson
Detoxification from High-Dose Zolpidem Using Diazepam
Ann. Pharmacother., April 1, 2004; 38(4): 590 - 594.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. J. Greenblatt, J. S. Harmatz, L. L. von Moltke, C. E. Wright, A. L. B. Durol, L. M. Harrel-Joseph, and R. I. Shader
Comparative Kinetics and Response to the Benzodiazepine Agonists Triazolam and Zolpidem: Evaluation of Sex-Dependent Differences
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 435 - 443.
[Abstract] [Full Text]


homecopy help contact us subscription past issues search current issue
Copyright © 1997 by Harvey Whitney Books Company.